Laroprovstat clinical trials
Also written AZD0780.
How each study uses laroprovstat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the laroprovstat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
17 studies that test it; most in 2024 (7)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 7 |
| 2025 | 5 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 17 · Other 0
Often tested with
Tested in the same studies.
Rosuvastatin (2) · AZD4954 (1) · Bempedoic acid (1) · Ethinyl estradiol, levonorgestrel drug combination (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 3 in phase 3
Studies that test laroprovstat, phase 3 first.
- Jan 2027A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFHPhase 3 · AstraZeneca
- Jan 2027A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD EventPhase 3 · AstraZeneca
- Feb 2027A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With DyslipidaemiaPhase 2/3 · AstraZeneca
Studies
Open first, then newest update. How each study uses laroprovstat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First EventRecruitingPhase 3AstraZenecaNCT07000357Written as AZD0780
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With DyslipidaemiaActive, not recruitingPhase 2/3AstraZenecaNCT06834932Written as AZD0780
- Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780CompletedPhase 1AstraZenecaNCT06576765Written as AZD0780
- A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFHActive, not recruitingPhase 3AstraZenecaNCT07000136Written as AZD0780
- A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 YearsCompletedPhase 1AstraZenecaNCT07216131Written as AZD0780
- A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With DyslipidaemiaCompletedPhase 2AstraZenecaNCT07218900Written as AZD0780
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy SubjectsCompletedPhase 1AstraZenecaNCT05384262Written as AZD0780
- A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD EventActive, not recruitingPhase 3AstraZenecaNCT07000123Written as AZD0780
- A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy AdultsCompletedPhase 1AstraZenecaNCT07513571Written as Laroprovstat
- A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C LevelsCompletedPhase 1AstraZenecaNCT07423598Written as AZD0780
- A Study to Assess the Effect of AZD0780 on Ambulatory Blood PressureCompletedPhase 2AstraZenecaNCT06692764Written as AZD0780
- A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With DyslipidemiaCompletedPhase 2AstraZenecaNCT06173570Written as AZD0780
- A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.CompletedPhase 1AstraZenecaNCT06742853Written as AZD0780
- An ADME Study of [14C]AZD0780 in Healthy Male SubjectsCompletedPhase 1AstraZenecaNCT05817461Written as AZD0780 tablet
- A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.CompletedPhase 1AstraZenecaNCT05787002Written as AZD0780
- An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug InteractionsCompletedPhase 1AstraZenecaNCT06671405Written as AZD0780
- A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780CompletedPhase 1AstraZenecaNCT06592482Written as AZD0780
As the comparator · 2 — what is tested is compared with laroprovstat
- A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve PatientsNot yet recruitingPhase 3AstraZenecaNCT07930507Written as Laroprovstat
- A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.RecruitingPhase 3AstraZenecaNCT07619131Written as Laroprovstat
Codes
What other systems call laroprovstat · ClinicalTrials.gg INT015852
- UNII (FDA) 9EEL3YMY29LAROPROVSTATOne source FDA
- NCI Thesaurus C211749LaroprovstatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 9EEL3YMY29 | LAROPROVSTAT | One source FDA |
| NCI Thesaurus | C211749 | Laroprovstat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.